Aim: To determine the efficacy of the doxycycline and trifarotene combination in treating acne vulgaris. Material and methods: A department of dermatology did an observational study. The research had a study population consisting of 50 participants. The randomization technique was stratified according to study center utilizing an interactive response technology system. The clinical study followed established and generally acknowledged protocols, as detailed in the Supplemental Information. Inclusion criteria for the study required participants to have moderate facial and truncal AV, as assessed by baseline IGA score of 3, with specific lesion counts on the face and trunk. The study enrolled individuals aged 18-40 with a minimum of 20 inflammatory lesions and 25 noninflammatory lesions on the face, as well as 20 to 100 inflammatory lesions and 20 noninflammatory lesions on the trunk. Results: Notably, 4% of participants experienced improvement during the initial 1-2 weeks, with a consistent increase in improvement percentages observed at subsequent intervals: 12% at 3-4 weeks, 20% at 5-6 weeks, 30% at 7-8 weeks, and a significant 34% at 9-10 weeks. Notably, 38% of patients reported a 'good' response, making it the most frequently observed reaction, followed by 'excellent' at 26%. Conclusion: we examines a new treatment technique that combines doxycycline and trifarotene for mild facial and truncal acne vulgaris. The study aims to investigate the differences in how people with different skin types respond to therapy. The study's rigor is emphasized by the strict adherence to recognized standards, stratified randomization, and the use of a fourth-generation topical retinoid called trifarotene.